Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.

Abstract

The trials comparing tight control arms show in general that the more intensive the strategy, the more strict the treatment aim and the more tight the tight control, the better the remission rates. It does not appear obligatory to start with a biological DMARD to get good results in tight control studies.